METHODS	Patients given danoprevir who had an extended rapid virologic response ( eRVR4-20 : HCV RNA < 15 IU/mL during weeks 4-20 ) stopped therapy at week 24 ; those without an eRVR4-20 continued therapy to 48 weeks .\